NCCN GUIDELINES® UPDATES June 2020

Cont. from page xxx. • Subsequent options for CHL: ► 1 1 was added, with corresponding footnote: Budde LE, Wu D, Martin DB, et al. Bendamustine with rituximab, etoposide and carboplatin (T(R)EC) in relapsed or refractory aggressive lymphoma: a prospective multicentre phase 1/2 clinical trial. Br J Haematol 2018;183:601-607. ► GEMOX (, ) was added, with corresponding footnote: Gutierrez A, Rodriguez J, Martinez-Serra J, et al. Gemcitabine andoxaliplatinum:aneffectiveregimeninpatientswithrefractory and relapsing . Onco Targets Ther 2014;7: 2093-2100. ► C-MOPP (, , , prednisone) was changed from a category 2B to a category 2A recommendation. • Footnote “c” was added. • Reference 25 (for pembrolizumab) was updated: Chen R, Zinzani PL, Fanale MA, et al. Phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic Hodgkin lymphoma. J Clin Oncol 2017;35(19):2125-2132.

HODG-F (1 of 2) • Brentuximab vedotin followed by AVD conditionally followed by brentuximab vedotin in responding patients with CR or PR was added to options for stage I–II unfavorable or stage III–IV disease, for older adults (age .60), with corresponding footnote: Evens AM, Advani RH, Helenowski IB, et al. Multicenter phase II study of sequential brentuximab vedotin and , , and for older patients with untreated classical Hodgkin lymphoma. J Clin Oncol 2018;36:3015-3022.

Erratum Erratum to: Cutler and Pavletic. NCCN Guidelines: Pretransplant Recipient Evaluation and Management of Graft-Versus-Host Disease. J Natl Compr Canc Netw 2020;18(5):645–647. In the May issue of JNCCN—Journal of the National Comprehensive Cancer Network, the doi for the article, “NCCN Guidelines: Pretransplant Recipient Evaluation and Management of Graft-Vs-Host Disease,” by Cutler and Pavletic (pages 645–647) was printed incorrectly. The correct doi is 10. 6004/jnccn.2020.7575. This has been corrected online at JNCCN.org. The editorial office apologizes for the error. doi: 10.6004/jnccn.2020.2001

xxxii © JNCCN—Journal of the National Comprehensive Cancer Network | Volume 18 Issue 6 | June 2020